180 Life Sciences Corp. (ATNF)
1.17
0.00 (0.00%)
At close: Feb 28, 2025, 3:59 PM
1.17
0.43%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.13 |
| Market Cap | 3.7M |
| Revenue (ttm) | 537.89K |
| Net Income (ttm) | -10.11M |
| EPS (ttm) | 7.98 |
| PE Ratio (ttm) | 0.15 |
| Forward PE | -3.2 |
| Analyst | n/a |
| Ask | 1.2 |
| Volume | 35,975 |
| Avg. Volume (20D) | 437,396 |
| Open | 1.14 |
| Previous Close | 1.17 |
| Day's Range | 1.12 - 1.21 |
| 52-Week Range | 1.10 - 17.75 |
| Beta | 0.14 |
About ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials t...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATNF
Website https://180lifesciences.com
2 months ago
-24.03%
180 Life Sciences Corp. shares are trading lower a...
Unlock content with
Pro Subscription
4 months ago
+9.79%
180 Life Sciences shares are trading higher after Elray Resources completed a sale of proprietary technology to the company to assist in the launch of an iGaming Blockchain casino.
2 years ago · businesswire.com
Elicit Plant beruft Pam Marrone und Johan de Saegher in den VorstandMOULINS-SUR-TARDOIRE, Frankreich--(BUSINESS WIRE)--Elicit Plant, ein Agro-Biotechnologieunternehmen, das sich auf die Resistenz von Nutzpflanzen gegen Wasserstress auf Basis einer phytosterolbasierten...
